Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prof. Scott Emerson On the Choice of Orderings of the Outcome Space (an introduction)

Published byReynold Harrison Modified over 9 years ago

Similar presentations

Presentation on theme: "Prof. Scott Emerson On the Choice of Orderings of the Outcome Space (an introduction)"— Presentation transcript:

1 Prof. Scott Emerson On the Choice of Orderings of the Outcome Space (an introduction)

2 Scott Emerson -in his own words “Unedited Stata output is TOTALLY unacceptable” BIOST 517, lecture 1

3 Scott Emerson -in his own words “Unedited Stata output is TOTALLY unacceptable” BIOST 517, lecture 1

4 Scott Emerson -more of his own words “Everything is regression” “I’m really into that band Sparklehorse” Fennerty MB, Emerson SS et al: Are endoscopic measurements of colonic polyps reliable? Am J Gastroenterology, 1993.

5 Scott Emerson -more of his own words “Everything is regression” “I’m really into that band Sparklehorse” Fennerty MB, Emerson SS et al: Are endoscopic measurements of colonic polyps reliable? Am J Gastroenterology, 1993.

6 Scott Emerson -some career highlights Lanciani, Emerson et al: Photoperiod- induced changes in metabolic response to temperature in drosophila melanogasterLanciani, Emerson et al: Photoperiod- induced changes in metabolic response to temperature in drosophila melanogaster Member, Data Safety Monitoring Board, Clinical Trial in Treatment of Nausea and Vomiting in Chemotherapy Member, Data Safety Monitoring Board, Clinical Trial in Treatment of Nausea and Vomiting in Chemotherapy Gillen & Emerson: Non-transitivity in a class of weighted logrank statistics under nonproportional hazards. (in press)Gillen & Emerson: Non-transitivity in a class of weighted logrank statistics under nonproportional hazards. (in press)

7 Scott Emerson -some career highlights Lanciani, Emerson et al: Photoperiod- induced changes in metabolic response to temperature in drosophila melanogasterLanciani, Emerson et al: Photoperiod- induced changes in metabolic response to temperature in drosophila melanogaster Member, Data Safety Monitoring Board, Clinical Trial in Treatment of Nausea and Vomiting in Chemotherapy Member, Data Safety Monitoring Board, Clinical Trial in Treatment of Nausea and Vomiting in Chemotherapy Gillen & Emerson: Non-transitivity in a class of weighted logrank statistics under nonproportional hazards. (in press)Gillen & Emerson: Non-transitivity in a class of weighted logrank statistics under nonproportional hazards. (in press)

8 Scott Emerson On the Choice of Orderings of the Outcome Space

Download ppt "Prof. Scott Emerson On the Choice of Orderings of the Outcome Space (an introduction)"

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Index Values NATIONAL STATISTICAL COORDINATION BOARD.

Index Values NATIONAL STATISTICAL COORDINATION BOARD.
1 MT vs CT: 28 day survival 10779969378958811223 10469398678268011223 Number at risk CT MT 868 779 0 25 50 75 100 051015202528 day % Surviving Monotherapy.

1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy.
BIOST 536 Lecture 18 1 Lecture 18 – Multinomial and Ordinal Regression Models.

BIOST 536 Lecture 18 1 Lecture 18 – Multinomial and Ordinal Regression Models.
Chemotherapy.

Chemotherapy.
Western Research Laboratories Thyroid Products Clinical Outcomes of Treatment.

Western Research Laboratories Thyroid Products Clinical Outcomes of Treatment.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:2742-53.

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:
Digestive System By: Briar Greene. Esophagus Stomach Small Intestine Large Intestine Rectum Anus Mouth Teeth Tongue/Saliva Liver Pancreas Gall Bladder.

Digestive System By: Briar Greene. Esophagus Stomach Small Intestine Large Intestine Rectum Anus Mouth Teeth Tongue/Saliva Liver Pancreas Gall Bladder.
Introduction Sample Size Calculation for Comparing Strategies in Two-Stage Randomizations with Censored Data Zhiguo Li and Susan Murphy Institute for Social.

Introduction Sample Size Calculation for Comparing Strategies in Two-Stage Randomizations with Censored Data Zhiguo Li and Susan Murphy Institute for Social.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Hungarian Pancreatic Study Group – Magyar Hasnyálmirigy Munkacsoport Gábor Lakatos 09 november 2015 4 th Conference of the Hungarian & 2 nd Conference.

Hungarian Pancreatic Study Group – Magyar Hasnyálmirigy Munkacsoport Gábor Lakatos 09 november th Conference of the Hungarian & 2 nd Conference.
ASSOCIATION BETWEEN ABDOMINAL COMPLAINTS AND NARCOTIC USE AMONG PATIENTS WITH SHORT BOWEL SYNDROME RECEIVING TEDUGLUTIDE Ken Fujioka, 1 Khursheed Jeejeebhoy,

ASSOCIATION BETWEEN ABDOMINAL COMPLAINTS AND NARCOTIC USE AMONG PATIENTS WITH SHORT BOWEL SYNDROME RECEIVING TEDUGLUTIDE Ken Fujioka, 1 Khursheed Jeejeebhoy,
TEDUGLUTIDE, A RECOMBINANT ANALOG OF GLP-2, REDUCES PARENTERAL SUPPORT IN PATIENTS WITH SHORT BOWEL SYNDROME REGARDLESS OF ULTRA-SHORT REMNANT BOWEL AND/OR.

TEDUGLUTIDE, A RECOMBINANT ANALOG OF GLP-2, REDUCES PARENTERAL SUPPORT IN PATIENTS WITH SHORT BOWEL SYNDROME REGARDLESS OF ULTRA-SHORT REMNANT BOWEL AND/OR.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.

Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

Similar presentations

Ads by Google